Incorporation of Ion Exchange Functionalized-montmorillonite into Solid Lipid Nanoparticles with Low Irritation Enhances Drug Bioavailability for Glaucoma Treatment

Overview

Journal Drug Deliv

Specialty Pharmacology

Date 2020 Apr 30

PMID 32347126

Citations 9

Authors

Shuo Liu

Xinyue Han

Hanyu Liu

Yawen Zhao

Huamei Li

Ilva D Rupenthal

Zhufen Lv

Yanzhong Chen

Fan Yang

Qineng Ping

Yufang Pan

Dongzhi Hou

Affiliations

Soon will be listed here.

Abstract

Montmorillonite-loaded solid lipid nanoparticles with good biocompatibility, using Betaxolol hydrochloride as model drug, were prepared by the melt-emulsion sonication and low temperature-solidification methods and drug bioavailability was significantly improved in this paper for the first time to application to the eye. The appropriate physical characteristics were showed, such as the mean particle size, Zeta potential, osmotic pressure, pH values, entrapping efficiency (EE%) and drug content (DC%), all showed well suited for possible ocular application. release experiment indicated that this novel system could continuously release 57.83% drugs within 12 h owing to the dual drug controlled-release effect that was achieved by ion-exchange feature of montmorillonite and structure of solid lipid nanoparticles. Low irritability and good compatibility of nanoparticles were proved by both CAM-TBS test and cytotoxicity experiment. We first discovered from the results of Rose Bengal experiment that the hydrophilicity of the drug-loaded nanoparticles surface was increased during the loading and releasing of the hydrophilic drug, which could contribute to prolong the ocular surface retention time of drug in the biological interface membrane of tear-film/cornea. The results of pharmacokinetic and pharmacodynamics studies further confirmed that increased hydrophilicity of nanoparticles surface help to improve the bioavailability of the drug and reduce intraocular pressure during administration. The results suggested this novel drug delivery system could be potentially used as an in situ drug controlled-release system for ophthalmic delivery to enhance the bioavailability and efficacy.

Citing Articles

Novel Biomaterials in Glaucoma Treatment.

Klezlova A, Bulir P, Klapstova A, Netukova M, Senkova K, Horakova J Biomedicines. 2024; 12(4).

PMID: 38672168 PMC: 11048501. DOI: 10.3390/biomedicines12040813.

Breaking Barriers in Eye Treatment: Polymeric Nano-Based Drug-Delivery System for Anterior Segment Diseases and Glaucoma.

Wu K, Ashkar S, Jain S, Marchand M, Tran S Polymers (Basel). 2023; 15(6).

PMID: 36987154 PMC: 10054733. DOI: 10.3390/polym15061373.

Solid Lipid Nanoparticles: Multitasking Nano-Carriers for Cancer Treatment.

German-Cortes J, Vilar-Hernandez M, Rafael D, Abasolo I, Andrade F Pharmaceutics. 2023; 15(3).

PMID: 36986692 PMC: 10056426. DOI: 10.3390/pharmaceutics15030831.

ROS generation and p-38 activation contribute to montmorillonite-induced corneal toxicity in vitro and in vivo.

Liu J, Yang S, Zhao L, Jiang F, Sun J, Peng S Part Fibre Toxicol. 2023; 20(1):8.

PMID: 36899356 PMC: 9999669. DOI: 10.1186/s12989-023-00519-9.

Physicochemical properties and micro-interaction between micro-nanoparticles and anterior corneal multilayer biological interface film for improving drug delivery efficacy: the transformation of tear film turnover mode.

Li H, Dai F, Liu H, Tao Q, Hu J, Zhang Y Drug Deliv. 2023; 30(1):2184312.

PMID: 36866574 PMC: 9987732. DOI: 10.1080/10717544.2023.2184312.

References

Lee M, Lim S, Kim C . Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials. 2007; 28(12):2137-46. DOI: 10.1016/j.biomaterials.2007.01.014. View

Yavuz B, Kompella U . Ocular Drug Delivery. Handb Exp Pharmacol. 2016; 242:57-93. DOI: 10.1007/164_2016_84. View

Vinardell M, Garcia L . The quantitive chlorioallantoic membrane test using trypan blue stain to predict the eye irritancy of liquid scintillation cocktails. Toxicol In Vitro. 2000; 14(6):551-5. DOI: 10.1016/s0887-2333(00)00050-3. View

Chatterjee A, Kumar L, Bhowmik B, Gupta A . Microparticulated anti-HIV vaginal gel: in vitro-in vivo drug release and vaginal irritation study. Pharm Dev Technol. 2010; 16(5):466-73. DOI: 10.3109/10837450.2010.485318. View

Angius F, Floris A . Liposomes and MTT cell viability assay: an incompatible affair. Toxicol In Vitro. 2014; 29(2):314-9. DOI: 10.1016/j.tiv.2014.11.009. View

Yellepeddi V, Sheshala R, McMillan H, Gujral C, Jones D, Raghu Raj Singh T . Punctal plug: a medical device to treat dry eye syndrome and for sustained drug delivery to the eye. Drug Discov Today. 2015; 20(7):884-9. DOI: 10.1016/j.drudis.2015.01.013. View

Dos Santos B, Bacalhau F, Dos Santos Pereira T, Souza C, Faez R . Chitosan-Montmorillonite microspheres: A sustainable fertilizer delivery system. Carbohydr Polym. 2015; 127:340-6. DOI: 10.1016/j.carbpol.2015.03.064. View

Baig M, Ahad A, Aslam M, Imam S, Aqil M, Ali A . Application of Box-Behnken design for preparation of levofloxacin-loaded stearic acid solid lipid nanoparticles for ocular delivery: Optimization, in vitro release, ocular tolerance, and antibacterial activity. Int J Biol Macromol. 2016; 85:258-70. DOI: 10.1016/j.ijbiomac.2015.12.077. View

Cremers T, Flik G, Hofland C, Stratford Jr R . Microdialysis evaluation of clozapine and N-desmethylclozapine pharmacokinetics in rat brain. Drug Metab Dispos. 2012; 40(10):1909-16. DOI: 10.1124/dmd.112.045682. View

10.

Georgiev G, Eftimov P, Yokoi N . Contribution of Mucins towards the Physical Properties of the Tear Film: A Modern Update. Int J Mol Sci. 2019; 20(24). PMC: 6941008. DOI: 10.3390/ijms20246132. View

11.

Chen D, Foldvari M . In vitro bioassay model for screening non-viral neurotrophic factor gene delivery systems for glaucoma treatment. Drug Deliv Transl Res. 2016; 6(6):676-685. DOI: 10.1007/s13346-016-0324-9. View

12.

Erkin E, Celik P, Kayikcioglu O, Deveci H, Sakar A . Effects of latanoprost and betaxolol on cardiovascular and respiratory status of newly diagnosed glaucoma patients. Ophthalmologica. 2006; 220(5):332-7. DOI: 10.1159/000094625. View

13.

Kumar L, Reddy M, Shirodkar R, Pai G, Krishna V, Verma R . Preparation and characterisation of fluconazole vaginal films for the treatment of vaginal candidiasis. Indian J Pharm Sci. 2014; 75(5):585-90. PMC: 3877521. View

14.

Kamata K, Inazu M, Takeda H, Goto H, Matsumiya T, Usui M . Effect of a selective inducible nitric oxide synthase inhibitor on intraocular nitric oxide production in endotoxin-induced uveitis rabbits: in vivo intraocular microdialysis study. Pharmacol Res. 2003; 47(6):485-91. DOI: 10.1016/s1043-6618(03)00057-4. View

15.

Fathalla Z, Vangala A, Longman M, Khaled K, Hussein A, El-Garhy O . Poloxamer-based thermoresponsive ketorolac tromethamine in situ gel preparations: Design, characterisation, toxicity and transcorneal permeation studies. Eur J Pharm Biopharm. 2017; 114:119-134. DOI: 10.1016/j.ejpb.2017.01.008. View

16.

Chen X, Sullivan D, Sullivan A, Kam W, Liu Y . Toxicity of cosmetic preservatives on human ocular surface and adnexal cells. Exp Eye Res. 2018; 170:188-197. DOI: 10.1016/j.exer.2018.02.020. View

17.

Louis K, Siegel A . Cell viability analysis using trypan blue: manual and automated methods. Methods Mol Biol. 2011; 740:7-12. DOI: 10.1007/978-1-61779-108-6_2. View

18.

Read M, Navascues-Cornago M, Keir N, Maldonado-Codina C, Morgan P . The impact of contact lens wear on ocular surface mucins using a novel clinical fluorescence imaging system. Cont Lens Anterior Eye. 2019; 43(4):378-388. DOI: 10.1016/j.clae.2019.08.004. View

19.

Chetoni P, Monti D, Tampucci S, Matteoli B, Ceccherini-Nelli L, Subissi A . Liposomes as a potential ocular delivery system of distamycin A. Int J Pharm. 2015; 492(1-2):120-6. DOI: 10.1016/j.ijpharm.2015.05.055. View

20.

Seyfoddin A, Shaw J, Al-Kassas R . Solid lipid nanoparticles for ocular drug delivery. Drug Deliv. 2010; 17(7):467-89. DOI: 10.3109/10717544.2010.483257. View